According to the studies, as many as 69% of COVID-19 patients suffer from long COVID – a range of new, recurrent, or ongoing problems 4 or more weeks following initial SARS-CoV-2 infection. Long COVID has been associated with acute disease severity, and is suspected to be related to autoimmune factors and unresolved viral fragments.
Studies found that the presence of autoantibodies in peripheral blood at initial diagnosis is one of the chief factors predicting if a patient would experience long COVID, along with having type 2 diabetes, SARS-CoV-2 RNAemia, and Epstein-Barr virus (EBV) viremia. EBV was reported to be reactivated by COVID infection. These autoantibodies can reduce anti–SARS-CoV-2 antibodies during COVID-19 infection.
Studies also identified an association between T2 hyperinflammation and long COVID–anticipating autoantibodies. This association further implies that hyperinflammation-controlling therapies in the acute stage of COVID may influence whether a patient experiences long COVID.
--Wenqi Song
No comments:
Post a Comment